CN108130373A - 在人pi3kca (pik3ca)基因中检测突变的方法和组合物 - Google Patents
在人pi3kca (pik3ca)基因中检测突变的方法和组合物 Download PDFInfo
- Publication number
- CN108130373A CN108130373A CN201810088883.4A CN201810088883A CN108130373A CN 108130373 A CN108130373 A CN 108130373A CN 201810088883 A CN201810088883 A CN 201810088883A CN 108130373 A CN108130373 A CN 108130373A
- Authority
- CN
- China
- Prior art keywords
- artificial sequence
- oligonucleotides
- dna
- annotation
- source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 69
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 108091034117 Oligonucleotide Proteins 0.000 claims description 114
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 110
- 125000003729 nucleotide group Chemical group 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 57
- 239000000523 sample Substances 0.000 claims description 32
- 102200085790 rs121913281 Human genes 0.000 claims description 23
- 108700028369 Alleles Proteins 0.000 claims description 19
- 102200085789 rs121913279 Human genes 0.000 claims description 18
- 102200085641 rs121913273 Human genes 0.000 claims description 17
- 102200085635 rs121913274 Human genes 0.000 claims description 17
- 102200085637 rs121913274 Human genes 0.000 claims description 17
- 102200085788 rs121913279 Human genes 0.000 claims description 17
- 102200085787 rs121913283 Human genes 0.000 claims description 17
- 102200085791 rs121913286 Human genes 0.000 claims description 17
- 102200085792 rs121913286 Human genes 0.000 claims description 17
- 102220197790 rs397517201 Human genes 0.000 claims description 17
- 102200085639 rs104886003 Human genes 0.000 claims description 16
- 102220197894 rs121913277 Human genes 0.000 claims description 16
- 239000011541 reaction mixture Substances 0.000 claims description 11
- 102220006545 c.1035C>A Human genes 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000003835 nucleoside group Chemical group 0.000 claims description 4
- 239000013610 patient sample Substances 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 3
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 5
- 230000007717 exclusion Effects 0.000 claims 1
- 102200066687 rs1554698949 Human genes 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 8
- 102000053900 human PI3KCA Human genes 0.000 abstract 2
- 108700026093 human PI3KCA Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 description 232
- 230000015572 biosynthetic process Effects 0.000 description 151
- 238000003786 synthesis reaction Methods 0.000 description 150
- 230000004048 modification Effects 0.000 description 80
- 238000012986 modification Methods 0.000 description 80
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 19
- 238000001514 detection method Methods 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 108091007960 PI3Ks Proteins 0.000 description 8
- 102000038030 PI3Ks Human genes 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 102220197892 rs121913284 Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 101150037123 APOE gene Proteins 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002342 ribonucleoside Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241001212017 Brana Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000006487 butyl benzyl group Chemical group 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780017P | 2013-03-13 | 2013-03-13 | |
| US61/780017 | 2013-03-13 | ||
| CN201480013282.7A CN105229171A (zh) | 2013-03-13 | 2014-03-12 | 在人pi3kca (pik3ca)基因中检测突变的方法和组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480013282.7A Division CN105229171A (zh) | 2013-03-13 | 2014-03-12 | 在人pi3kca (pik3ca)基因中检测突变的方法和组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108130373A true CN108130373A (zh) | 2018-06-08 |
Family
ID=50277211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810088883.4A Pending CN108130373A (zh) | 2013-03-13 | 2014-03-12 | 在人pi3kca (pik3ca)基因中检测突变的方法和组合物 |
| CN201480013282.7A Pending CN105229171A (zh) | 2013-03-13 | 2014-03-12 | 在人pi3kca (pik3ca)基因中检测突变的方法和组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480013282.7A Pending CN105229171A (zh) | 2013-03-13 | 2014-03-12 | 在人pi3kca (pik3ca)基因中检测突变的方法和组合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140272961A1 (enExample) |
| EP (1) | EP2971075B1 (enExample) |
| JP (1) | JP6453781B2 (enExample) |
| CN (2) | CN108130373A (enExample) |
| CA (1) | CA2899712C (enExample) |
| ES (1) | ES2691306T3 (enExample) |
| WO (1) | WO2014140061A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109913481A (zh) * | 2019-04-24 | 2019-06-21 | 无锡市第五人民医院 | PIK3CA基因g.1792224821G>A突变及其在乳腺癌辅助诊断中的应用 |
| CN114410790A (zh) * | 2022-01-27 | 2022-04-29 | 湖南大学 | 一种用于检测ctDNA的生物传感检测系统及其检测方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| CN109923121B (zh) | 2016-11-22 | 2022-12-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
| KR102813811B1 (ko) * | 2020-03-27 | 2025-05-30 | 주식회사 젠큐릭스 | Pik3ca 돌연변이 검출용 조성물 및 이를 포함하는 키트 |
| CN111363827A (zh) * | 2020-04-30 | 2020-07-03 | 北京和合医学诊断技术股份有限公司 | 用于检测pik3ca基因突变的引物组及其应用方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102119222A (zh) * | 2007-09-28 | 2011-07-06 | Dxs有限公司 | 多核苷酸引物 |
| WO2012020965A2 (ko) * | 2010-08-13 | 2012-02-16 | 주식회사 파나진 | Ｐｎａ의 실시간 ｐｃｒ 클램핑을 이용한 ｐｉｋ3ｃａ 돌연변이 검출 방법 및 키트 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3556866T (pt) * | 2004-03-02 | 2021-04-30 | Univ Johns Hopkins | Mutações do gene de pik3ca em cancros humanos |
| JP5624044B2 (ja) * | 2008-10-20 | 2014-11-12 | エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改善されたアレル−特異的増幅 |
| US20100286143A1 (en) * | 2009-04-24 | 2010-11-11 | Dora Dias-Santagata | Methods and materials for genetic analysis of tumors |
| US9238832B2 (en) * | 2009-12-11 | 2016-01-19 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids |
| US8940486B2 (en) * | 2010-01-12 | 2015-01-27 | Siemens Healthcare Diagnostics Inc. | Oligonucleotides and methods for detecting KRAS and PIK3CA mutations |
| CN102234685B (zh) * | 2010-04-23 | 2014-08-27 | 益善生物技术股份有限公司 | 一种pik3ca基因突变检测液相芯片 |
| WO2013041194A1 (en) * | 2011-09-23 | 2013-03-28 | Roche Diagnostics Gmbh | Use of g-clamp for improved allele-specific pcr |
-
2014
- 2014-03-12 CA CA2899712A patent/CA2899712C/en active Active
- 2014-03-12 ES ES14709926.1T patent/ES2691306T3/es active Active
- 2014-03-12 CN CN201810088883.4A patent/CN108130373A/zh active Pending
- 2014-03-12 EP EP14709926.1A patent/EP2971075B1/en active Active
- 2014-03-12 CN CN201480013282.7A patent/CN105229171A/zh active Pending
- 2014-03-12 US US14/205,751 patent/US20140272961A1/en not_active Abandoned
- 2014-03-12 JP JP2015562104A patent/JP6453781B2/ja active Active
- 2014-03-12 WO PCT/EP2014/054766 patent/WO2014140061A2/en not_active Ceased
-
2016
- 2016-02-05 US US15/017,179 patent/US20160160297A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102119222A (zh) * | 2007-09-28 | 2011-07-06 | Dxs有限公司 | 多核苷酸引物 |
| WO2012020965A2 (ko) * | 2010-08-13 | 2012-02-16 | 주식회사 파나진 | Ｐｎａ의 실시간 ｐｃｒ 클램핑을 이용한 ｐｉｋ3ｃａ 돌연변이 검출 방법 및 키트 |
Non-Patent Citations (4)
| Title |
|---|
| DBSNP: "ss275515117", 《DBSNP》 * |
| RAJESH PATEL等: "Mutation Scanning Using MUT-MAP, a High-Throughput,Microfluidic Chip-Based, Multi-Analyte Panel", 《PLOS ONE》 * |
| 余多慰等: "《分子生物学》", 31 July 2007, 南京师范大学出版社 * |
| 蒋健坤等: "结直肠癌组织中PIK3CA基因突变与AKT1/2蛋白的表达及其意义", 《广西医学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109913481A (zh) * | 2019-04-24 | 2019-06-21 | 无锡市第五人民医院 | PIK3CA基因g.1792224821G>A突变及其在乳腺癌辅助诊断中的应用 |
| CN114410790A (zh) * | 2022-01-27 | 2022-04-29 | 湖南大学 | 一种用于检测ctDNA的生物传感检测系统及其检测方法 |
| CN114410790B (zh) * | 2022-01-27 | 2024-04-12 | 湖南大学 | 一种用于检测ctDNA的生物传感检测系统及其检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140272961A1 (en) | 2014-09-18 |
| CN105229171A (zh) | 2016-01-06 |
| EP2971075A2 (en) | 2016-01-20 |
| WO2014140061A2 (en) | 2014-09-18 |
| EP2971075B1 (en) | 2018-08-15 |
| US20160160297A1 (en) | 2016-06-09 |
| CA2899712A1 (en) | 2014-09-18 |
| WO2014140061A3 (en) | 2014-10-30 |
| JP2016510982A (ja) | 2016-04-14 |
| CA2899712C (en) | 2021-01-05 |
| JP6453781B2 (ja) | 2019-01-16 |
| ES2691306T3 (es) | 2018-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10023917B2 (en) | High resolution melting analysis as a prescreening tool | |
| CN103710460B (zh) | 定量检测egfr基因突变的试剂盒及其用途 | |
| JP5750710B2 (ja) | 癌マーカー、それを用いた癌の評価方法および評価試薬 | |
| CN103923975B (zh) | 一种检测egfr基因外显子19缺失突变的试剂盒和方法 | |
| CN105593378B (zh) | 用于在人ezh2基因中检测突变的方法和组合物 | |
| CN110964814B (zh) | 用于核酸序列变异检测的引物、组合物及方法 | |
| JP2014500028A (ja) | ヒト上皮成長因子受容体遺伝子内の突然変異を検出するための方法及び組成物 | |
| JP6438119B2 (ja) | ホットスポット変異の迅速かつ高感度の検出のための方法 | |
| CN108130373A (zh) | 在人pi3kca (pik3ca)基因中检测突变的方法和组合物 | |
| CN110541033B (zh) | Egfr基因突变检测用组合物及检测方法 | |
| JP2013081450A (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット | |
| CN105624296A (zh) | 基于arms荧光pcr法检测基因多态性的通用型荧光发夹引物 | |
| KR101857227B1 (ko) | 다중 증폭 이중 시그널 증폭에 의한 암 유전자 분석 방법 및 이를 위한 암 유전자 분석용 키트 | |
| JP6153758B2 (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
| JP6205216B2 (ja) | 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット | |
| JP7297902B2 (ja) | 分析方法及びキット | |
| CN116004812A (zh) | 检测甲基化水平的试剂在制备食管癌诊断产品中的应用以及食管癌诊断试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |